Last reviewed · How we verify
PanCytoVir™
At a glance
| Generic name | PanCytoVir™ |
|---|---|
| Sponsor | TrippBio, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml) (PHASE1)
- An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers (PHASE1)
- A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PanCytoVir™ CI brief — competitive landscape report
- PanCytoVir™ updates RSS · CI watch RSS
- TrippBio, Inc. portfolio CI